INSPIREMD INC (NSPR) Stock Price, Quote, News and Overview
NASDAQ:NSPR - Nasdaq - US45779A8466 - Common Stock - Currency: USD
NSPR Quote, Performance and Key Statistics
2.24
-0.23 (-9.49%)
The current stock price of NSPR is 2.24 USD. In the past month the price decreased by -10.04%. In the past year, price decreased by -10.23%.
NSPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.19 | 43.76B | ||
| COO | COOPER COS INC/THE | 17.92 | 13.91B | ||
| ALGN | ALIGN TECHNOLOGY INC | 20.06 | 13.56B | ||
| SOLV | SOLVENTUM CORP | 12.6 | 12.97B | ||
| LNTH | LANTHEUS HOLDINGS INC | 12.17 | 5.57B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 25.95 | 5.48B | ||
| BLCO | BAUSCH + LOMB CORP | 25.35 | 4.30B | ||
| HAE | HAEMONETICS CORP/MASS | 16.06 | 3.53B | ||
| ICUI | ICU MEDICAL INC | 18.92 | 3.25B | ||
| XRAY | DENTSPLY SIRONA INC | 9.52 | 3.19B | ||
| UFPT | UFP TECHNOLOGIES INC | 30.19 | 1.90B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.08B |
Related stock screener links
About NSPR
Company Profile
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Company Info
INSPIREMD INC
4 Menorat Hamaor St.
TEL AVIV-YAFO 6744832 IL
CEO: Marvin Slosman
Employees: 86
INSPIREMD INC / NSPR FAQ
What is the stock price of INSPIREMD INC today?
The current stock price of NSPR is 2.24 USD. The price decreased by -9.49% in the last trading session.
What is the ticker symbol for INSPIREMD INC stock?
The exchange symbol of INSPIREMD INC is NSPR and it is listed on the Nasdaq exchange.
On which exchange is NSPR stock listed?
NSPR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INSPIREMD INC stock?
8 analysts have analysed NSPR and the average price target is 4.59 USD. This implies a price increase of 104.91% is expected in the next year compared to the current price of 2.24. Check the INSPIREMD INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INSPIREMD INC worth?
INSPIREMD INC (NSPR) has a market capitalization of 68.63M USD. This makes NSPR a Micro Cap stock.
How many employees does INSPIREMD INC have?
INSPIREMD INC (NSPR) currently has 86 employees.
What are the support and resistance levels for INSPIREMD INC (NSPR) stock?
INSPIREMD INC (NSPR) has a support level at 2.23 and a resistance level at 2.47. Check the full technical report for a detailed analysis of NSPR support and resistance levels.
Is INSPIREMD INC (NSPR) expected to grow?
The Revenue of INSPIREMD INC (NSPR) is expected to grow by 4.48% in the next year. Check the estimates tab for more information on the NSPR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INSPIREMD INC (NSPR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NSPR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NSPR, evaluating the profitability, health, valuation and growth aspects
- INSPIREMD INC (NSPR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INSPIREMD INC (NSPR) Sales and EPS estimates to see what analysts future expectations are.
- INSPIREMD INC (NSPR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INSPIREMD INC (NSPR) Insider and Institutional Ownership to learn about the owners and their transactions.
- INSPIREMD INC (NSPR) Stock Chart to make your own analysis
- INSPIREMD INC (NSPR) Latest news and press-releases to stay up to date.
Does INSPIREMD INC (NSPR) stock pay dividends?
NSPR does not pay a dividend.
When does INSPIREMD INC (NSPR) report earnings?
INSPIREMD INC (NSPR) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of INSPIREMD INC (NSPR)?
INSPIREMD INC (NSPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
What is the Short Interest ratio of INSPIREMD INC (NSPR) stock?
The outstanding short interest for INSPIREMD INC (NSPR) is 1.03% of its float. Check the ownership tab for more information on the NSPR short interest.
NSPR Technical Analysis
NSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NSPR. The financial health of NSPR is average, but there are quite some concerns on its profitability.
NSPR Financial Highlights
Over the last trailing twelve months NSPR reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS decreased by -3.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.23% | ||
| ROE | -128.46% | ||
| Debt/Equity | 0 |
NSPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NSPR. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -31.42% and a revenue growth 4.48% for NSPR